Prolymphocytic leukaemia and Hodgkin's lymphoma

Naranjo, Tomás Álvaro; Matutes, Estella; Martínez, Joaquín Jaén; Ferré, Llorenç Font; Domingo, Alícia; Princep, R. Bosch; Usach, Teresa Salvadó

doi:10.1034/j.1600-0609.2002.02758.x

Cited by 4 publications

(2 citation statements)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68 More anecdotally, case reports indicate that fludarabine can induce CR in chlorambucil-resistant B-PLL, 69 including one account of a long-lasting response (5 years). 70 Finally, fludarabine also achieved a CR in one patient with B-PLL complicated by leukemic pleural effusion. 71 Hairy cell leukemia Hairy cell leukemia (HCL), previously known as leukemic reticuloendotheliosis, is an indolent disorder that accounts for about 2% of all leukemias.…”

Section: Cll Variantsmentioning

confidence: 98%

Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies

Johnson¹

2004

Hematol J

View full text Add to dashboard Cite

After initial efforts using fludarabine as a single agent in the treatment of acute leukemia, its activity at lower and safer doses was demonstrated in chronic lymphocytic leukemia (CLL) patients who were refractory or had relapsed from traditional chemotherapies, representing a highly effective therapy for this condition. Fludarabine was also rapidly shown to be beneficial as first-line therapy in CLL. There is now considerable evidence that fludarabine is an effective agent in non-Hodgkin's lymphoma and in combination therapy for acute myeloid leukemia. Further, good responses are achieved when fludarabine-based approaches are used as conditioning regimens prior to transplantation procedures. The actions of fludarabine are not restricted to these settings and its potential role in the treatment of a range of uncommon T- and B-cell lymphoid malignancies is slowly emerging. This review will focus on the characteristics and treatment options for two B-cell disorders, mantle cell lymphoma and Waldenström's macroglobulinemia, with emphasis on the clinical activity of fludarabine. Additionally, the advantages of using fludarabine-containing regimens for a range of other lymphoproliferative conditions will also be discussed. These include B-cell neoplasms such as the CLL variant prolymphocytic leukemia, hairy cell leukemia and mucosa-associated lymphoid tissue-derived lymphomas; the T-cell disorders cutaneous T-cell lymphoma, angioimmunoblastic lymphadenopathy and other rarer T-cell diseases; and aggressive variants of non-Hodgkin's lymphoma including Richter's syndrome.

show abstract

Section: Cll Variantsmentioning

confidence: 98%

Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies

Johnson¹

2004

Hematol J

View full text Add to dashboard Cite

show abstract

“…There are only a few reports concerning single patients treated with PNAs -2-CdA or FA-MP [172][173][174][175][176]. Palomera et al [176] described the previously untreated patients with T-cell PLL, who received 3 cycles of 2-CdA and obtained CR.…”

Section: Prolymphocytic Leukemiamentioning

confidence: 99%

Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications

Robak

Korycka²,

Kasznicki

et al. 2005

CCDT

View full text Add to dashboard Cite

The purine nucleoside analogues (PNAs), fludarabine (FA), 2-CdA (2-chlorodeoxyadenosine, 2-CdA) and pentostatin (2'-deoxycoformycin, DCF) represent a group of cytotoxic agents with high activity in lymphoid and myeloid malignancies. PNAs share similar chemical structure and mechanism of action. Several mechanisms could be responsible for their cytotoxicity both in proliferating and quiescent cells, such as inhibition of DNA synthesis, inhibition of DNA repair and accumulation of DNA strand breaks. Induction of apoptosis through the mitochondrial pathway, direct binding to apoptosome or modulation of p53 expression all lead to apoptosis, which is the main end-point of PNA action. However, individual PNAs exhibit significant differences, especially in their interaction with enzymes involved in adenosine and deoxyadenosine metabolism. Synergistic interactions between PNAs and other cytotoxic agents (alkylating agents, anthracycline antitumor antibiotics, cytarabine, monoclonal antibodies) have been demonstrated in both preclinical and clinical studies. PNAs are highly effective in chronic lymphoid leukemias and low grade B- and T-cell non-Hodgkin's lymphomas, including Waldenström's macroglobulinemia. DCF and 2-CdA are currently the drugs of choice in hairy cell leukemia. Moreover, clinical studies have confirmed the efficacy of PNAs alone or in combination protocols in the treatment of acute myeloid leukemia and myelodysplastic syndromes. Finally, PNAs, especially FA, play an important role in non-myeloablative conditioning regimens for allogenic stem cell transplantation in high-risk patients. The toxicity profiles of PNAs are similar for all agents and consist mainly of dose-limiting myelotoxicity and prolonged immunosuppression. Three other compounds: clofarabine, nelarabine and immucillin-H are currently being evaluated clinically.

show abstract

B‐Cell Neoplasms

Valli¹

2007

Veterinary Comparative Hematopathology

View full text Add to dashboard Cite

Prolymphocytic leukaemia and Hodgkin's lymphoma

Cited by 4 publications

References 8 publications

Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies

Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies

Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications

B‐Cell Neoplasms

Contact Info

Product

Resources

About